|
|
|
| A comparative study of MRI of renal clear cell carcinoma and papillary carcinoma |
| WANG Qian1 REN Jinwu1 YIN Yuanyuan2 ZHAO Zuhong1 WANG Shumei1 MA Congmin1▲ |
1.CT/MRI Room, Baoding First Central Hospital, Hebei Province, Baoding 071000, China;
2.MRI Room, China Armed Police General Hospital, Beijing 100039, China |
|
|
|
Abstract Objective To investigate the MRI of renal clear cell carcinoma and papillary carcinoma. Methods The clinical data of 85 patients with renal cell carcinoma admitted to Baoding First Central Hospital and China Armed Police General Hospital from May 2013 to May 2017 were retrospectively analyzed. Among the patients, 50 patients with renal clear cell carcinoma were included in the renal clear cell carcinoma group, and 35 patients with renal papillary carcinoma were included in the renal papillary carcinoma group. MRI scanning and dynamic enhancement imaging were compared between the two groups, and the lesion appearing and the tumor-cortical enhancement index were compared between the two groups. Results In renal clear cell carcinoma group, T1WI scanning showed low signal and mixed signal. The T1WI scanning of the renal papillary carcinoma group presented mixed signal, and the difference in the rate of low signal was statistically significant between the two groups (P ＜ 0.05). The T2WI scanning of the renal clear cell carcinoma group presented high signal and mixed signal, while the T2WI scanning of the renal papillary carcinoma group presented low signal and mixed signal, the difference in the proportion of high signal and mixed signal on T2WI between the two groups was statistically significant (P ＜ 0.05). MRI showed necrosis, neovascularization, and extrarenal invasion proportion in the renal clear cell carcinoma group, which was significantly higher than that in the papillary carcinoma group, while the rate of hemorrhage and cystic degeneration was significantly lower than that of the renal papillary carcinoma group, and the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). MRI in the renal clear cell carcinoma group showed progressive weakening from cortical phase to delayed phase (P ＜ 0.01). MRI in the renal papillary carcinoma group showed progressive mild enhancement from cortical phase to parenchymal phase, and decreased signal from parenchymal phase to delayed phase (P ＜ 0.01). The enhancement indices of cortical, parenchymal and delayed phases were significantly higher than those of papillary carcinoma group, the differences were highly statistically significant (P ＜ 0.01). Conclusion MRI of renal clear cell carcinoma and papillary carcinoma have certain characteristics, and the enhancement degree of each kidney cancer subtype can significantly differentiate renal clear cell carcinoma and papillary carcinoma.
|
|
|
|
|
|
[1] Miyake H，Matsushita Y，Watanabe H，et al. Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma [J]. Med Oncol，2018，35（10）：133.
[2] Williamson SR，Gupta NS，Eble JN，et al. Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma：Combined Morphologic，Immunohistochemical，and Cytogenetic Analysis [J]. Am J Surg Pathol，2015，39（11）：1502-1510.
[3] Xie J，Lin W，Huang L，et al. Bufalin suppresses the proliferation and metastasis of renal cell carcinoma by inhibiting the PI3K/Akt/mTOR signaling pathway [J]. Oncol Lett，2018，16（3）：3867-3873.
[4] 朱鑫，王亚轩，常学良，等.HDAC1及E2F1在肾透明细胞癌中的表达及意义[J].河北医药，2015，22（19）：2885-2888.
[5] 张远鸿，任海红，骆玉辉，等.增强CT MRI及超声造影对肾脏占位性病变的诊断价值比较[J].浙江临床医学，2016，18（8）：1388-1390.
[6] 徐明哲，刘爱连.MR功能成像在肾脏肿瘤中的应用进展[J].中国临床医学影像杂志，2018，29（2）：133-136.
[7] Li J，You J，Wu C，et al. T1-T2 molecular magnetic resonance imaging of renal carcinoma cells based on nano-contrast agents [J]. Int J Nanomedicine，2018，13：4607-4625.
[8] Reynolds HM，Parameswaran BK，Finnegan ME，et al. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy （SABR） of primary renal cell carcinoma [J]. PLoS One，2018，13（8）：e0202387.
[9] 沈丽娟，周良平.磁共振弥散加权成像技术在肾脏肿瘤诊断中的研究和进展[J].中国癌症杂志，2014，22（5）：387-391.
[10] 徐金升，王静，张俊霞，等.SET8在肾透明细胞癌中的表达及其对786-O细胞增殖迁移能力的影响[J].中华泌尿外科杂志，2016，37（11）：860-865.
[11] 孙连桃，肖伟利.巨噬细胞移动抑制因子在肾透明细胞癌组织中的表达与意义[J].中国老年学杂志，2017，37（24）：6113-6115.
[12] Li H，Li A，Zhu H，et al. Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Differentiation of Minimal Fat Angiomyolipoma from Clear Cell Renal Cell Carcinoma [J]. Acad Radiol，2018，6332（18）：30 329-30 335.
[13] Abdullah A，Lekkala M，Wolfe Z，et al. Isolated Left Ventricular Metastasis from Renal Cell Carcinoma：Diagnostic and Therapeutic Dilemma [J]. Case Rep Oncol，2018， 11（2）：365-371.
[14] Jeong D，Raghunand N，Hernando D，et al. Quantification of sarcomatoid differentiation in renal cell carcinoma on magnetic resonance imaging [J]. Quant Imaging Med Surg，2018，8（4）：373-382.
[15] Zhang WQ，Bao Y，Qiu B，et al. Clival metastasis of renal clear cell carcinoma：Case report and literature review [J]. World J Clin Cases，2018，6（9）：301-307.
[16] Little RA，Jamin Y，Boult JKR，et al. Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI：Comparison with Intrinsic Susceptibility MRI and Pathology [J]. Radiology，2018，288（3）：739-747.
[17] Kay FU，Pedrosa I. Imaging of Solid Renal Masses [J]. Urol Clin North Am，2018，45（3）：311-330.
[18] Adams LC，Ralla B，Engel G，et al. Assessing venous thrombus in renal cell carcinoma：preliminary results for unenhanced 3D-SSFP MRI [J]. Clin Radiol，2018，73（8）：757.e9-757.e19.
[19] Goyal A，Sharma R，Bhalla AS，et al. Comparison of MDCT，MRI and MRI with diffusion-weighted imaging in evaluation of focal renal lesions：The defender，challenger，and winner [J]. Indian J Radiol Imaging，2018，28（1）：27-36.
[20] Kitamura H，Kurokawa M，Inaki N，et al. Gallbladder Metastasis from Renal Cell Carcinoma [J]. Indian J Surg，2018，80（3）：278-280. |
|
|
|
